Acutaas Chemicals Q2 FY27 Revenue Surges 42.7% YoY to ₹4,369mn; PAT Up 71.4%
Acutaas Chemicals reported Q2 FY27 revenue of ₹4,369 million, up 42.7% YoY. PAT increased by 71.4% YoY to ₹1,231 million. The company inaugurated its South Korea manufacturing facility. FY27 revenue growth guidance revised upwards to ~30%, and EBITDA margin guidance raised to 38-40%.
The significant increase in revenue and profit, coupled with upward revisions in future guidance and strategic expansion into the semiconductor ecosystem, are material positive developments for the company.
The company reported strong year-on-year growth in revenue and profit, improved margins, and raised its future guidance. The inauguration of a new manufacturing facility also adds to the positive outlook.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has announced its financial results for the second quarter and half-year ended September 30, 2026. The company reported a significant year-on-year growth in revenue from operations for Q2 FY27, which stood at ₹4,369 million, marking a 42.7% increase from ₹3,062 million in Q2 FY26. Consolidated Profit After Tax (PAT) for the quarter also saw a substantial rise of 71.4% YoY, reaching ₹1,231 million, with PAT margins improving to 28.2% from 23.5% in the prior year period.
For the half-year ended September 30, 2026, consolidated revenue from operations grew by 49.3% YoY to ₹7,666 million, and PAT increased by 71.0% YoY to ₹1,981 million. The company's gross margin improved to 62.1% in Q2 FY27, and EBITDA grew by 84.6% YoY to ₹1,760 million, with EBITDA margins expanding to 40.3% from 31.1% in Q2 FY26.
Mr. Naresh Patel, Executive Chairman & Managing Director, highlighted the strong performance driven by the Pharmaceutical Intermediates business, despite a softer performance in the Specialty Chemicals segment. A key milestone was the early inauguration of their South Korea manufacturing facility, designed for high-purity chemicals for semiconductor applications. Based on improved revenue visibility and a robust order pipeline, Acutaas Chemicals has revised its FY27 revenue growth guidance upwards to around 30% from 25% and raised its EBITDA margin guidance to the 38-40% range.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.